A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2018
Price : $35 *
At a glance
- Drugs CPI 0610 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Constellation Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 06 Jun 2018 Status changed from recruiting to completed.
- 20 Feb 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2018.